Arotinolol
| Arotinolol | ||
|---|---|---|
| Naziv lijeka | Arotinolol | |
| Grupa | Blokatori β-receptora | |
| ||
| ATC kodovi | Nema | |
| CAS registarski broj | 41287-43-8 | |
| ||
| Stručne informacije | ||
| ||
 Ime po IUPAC (RS)-5-(2-{[3-(tert-butilamino)-2-hidroksipropil]sulfanil}- 1,3-tiazol-4-il)tiofen-2-karboksamid | ||
| Sumarna formula | C15H21N3O2S3 | |
| Molarna masa | 371,54 g/mol | |
| ||
| Biološka raspoloživost | 2 sata | |
| Poluvrijeme eliminacije | 10 sati PubChem = 2239 | |
Arotinolol (INN, u prometu pod trgovačkim nazivom Almarl) je lijek iz klase miješanih alfa/beta blokatora.[1] Također djeluje i kao β3 receptor agonist.[2] Jedna publikacija iz 1979 sugerira arotinolol kao prvoopisani u naučnoj literaturi, u Sumitomo Chemical kao "β-adrenergički blokirajući, antiaritmični spoj S-596.[3]
Upotreba
[uredi | uredi izvor]Arotinolol se upotrebljeva u liječenju visokog krvnog pritiska[4] i esencijalnog tremora.[5][6] Preporučeno doziranje je 10–30 mg dnevno.
Također pogledajte
[uredi | uredi izvor]Reference
[uredi | uredi izvor]- ^ Zhao, Jin; Golozoubova, Valeria; Cannon, Barbara; Nedergaard, Jan (juli 2001). "Arotinolol is a weak partial agonist on beta 3-adrenergic receptors in brown adipocytes". Can J Physiol Pharmacol. 79 (7): 585–593. doi:10.1139/cjpp-79-7-585. PMID 11478592.
- ^ Takahashi, H; Yoshida, T; Nishimura, M; Nakanishi, T; Kondo, M; Yoshimura, M (septembar 1992). "Beta-3 Adrenergic Agonist, BRL-26830A, and Alpha/Beta Blocker, Arotinolol, Markedly Increase Regional Blood Flow in the Brown Adipose Tissue in Anesthetized Rats". Japanese Circulation Journal. 56 (9): 936–42. doi:10.1253/jcj.56.936. PMID 1383578.
- ^ Hara, Youichi; Sato, Etsuro; Miyagishi, Akira; Aono, Shunzi; Nakatani, Hiroshi (1979). "新しいβ-受容体遮断薬，dl-2-(3'-t-Butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)-thiazole hydrochloride (S-596) の薬理作用" [Pharmacological properties of dl-2-(3'-t-butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)thiazole hydrochloride (S-596), a new β-adrenergic blocking agent]. Folia Pharmacologica Japonica (English abstract) (jezik: Japanese): 707–720. doi:10.1254/fpj.75.707. ISSN 1347-8397.CS1 održavanje: nepoznati jezik (link)
- ^ Wu, Haiying; Zhang, Yuqing; Huang, Jianfeng; Zhang, Yuhui; Liu, Guozhang; Sun, Ningling; Yu, Zhenqui; Zhou, Yanrong (septembar 2001). "Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers" (PDF). Hypertension Research. 24 (5): 605–10. doi:10.1291/hypres.24.605. ISSN 1348-4214. PMID 11675958.
- ^ Lee, Kwang-Soo; Kim, Joong-Seok; Kim, Jae-Woo; Lee, Won-Yong; Jeon, Beum-Seok; Kim, Dongjae (august 2003). "A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor" (PDF). Parkinsonism & Related Disorders. 9 (6): 341–347. doi:10.1016/S1353-8020(03)00029-4. PMID 12853233.
- ^ "Almarl (アルマール) Arotinolol HCl Tablets. Full Prescribing Information" (PDF). Sumitomo Dainippon Pharma Co., Ltd. Arhivirano s originala (PDF), 7. 5. 2012. Pristupljeno 6. 3. 2016.
Vanjski linkovi
[uredi | uredi izvor]- Japanski: Almarl Full Prescribing Information. Revised November 2009 Sumitomo Dainippon Pharma Co., Ltd.
- japanski: Official Sumitomo Dainippon Pharma Website Arhivirano 1. 7. 2020. na Wayback Machine
- https://web.archive.org/web/20110722132720/http://sdic.sookmyung.ac.kr/drug_monograph/view.asp?id=92